Fried Chicken Mushroom

Metadata

Regulatory Status

Japan

• Status: Lyophyllum decastes is commercially cultivated and widely sold in Japanese supermarkets under the name Hatakeshimeji. It is classified as a food product with no specific medicinal claims authorized.
• Culinary tradition: Hatakeshimeji has been cultivated commercially in Japan since the 1990s and is valued for its firm texture, mild flavor, and versatility in Japanese cuisine including nabemono (hot pot), tempura, and stir-fry dishes.
• Research context: Japanese researchers have been the primary investigators of its pharmacological properties, with key studies from Japanese institutions.

China

• Status: Consumed as an edible mushroom and cultivated commercially. Lyophyllum decastes polysaccharides have been extensively studied by Chinese research groups for immunomodulatory, hepatoprotective, and anti-colitis applications. Not listed in the Chinese Pharmacopoeia as a medicinal substance.

United States

• Status: Not widely available commercially in the US market. No FDA GRAS determination. Not commonly marketed as a dietary supplement. Found occasionally at specialty mushroom farms and Asian grocery stores.

European Union

• Status: Consumed as a wild-harvested and cultivated edible mushroom in parts of Europe. No novel food authorization specifically for L. decastes extracts or supplements. The fruiting body as a food does not require novel food authorization.

Conditions & Indications

Primary Indications (Preclinical Evidence)

• Immune modulation and antitumor activity — Beta-glucan polysaccharides (IV-1, IV-2, IV-3) purified from L. decastes fruiting bodies demonstrated marked antitumor activity against Sarcoma 180 in BALB/c mice. The beta-1,3-D-glucan fraction (IV-1, 305 kDa) and the beta-1,6-D-glucan fraction (IV-3, 14 kDa) both showed significant tumor inhibition through immunological host-mediated mechanisms, evidenced by increased peritoneal macrophages and complement C3-positive cells.
• Lipid metabolism and hypocholesterolemia — Dietary supplementation with L. decastes fruiting body powder (10% of diet) or hot water extract significantly reduced serum total cholesterol in rats fed a cholesterol-containing diet. The mechanism involves increased cholesterol 7-alpha-hydroxylase activity, which converts cholesterol to bile acids, and enhanced fecal bile acid excretion.

Secondary Indications (Preclinical Evidence)

• Antidiabetic activity — Water extract of L. decastes (500 mg/kg) reduced blood glucose in genetically diabetic KK-Ay mice after both single oral administration (7 hours) and repeated administration (3 weeks), with significant reduction in serum insulin levels, suggesting improved insulin sensitivity rather than increased insulin secretion.
• Hepatoprotection — L. decastes fruiting body polysaccharide (LDFP) protected against CCl4-induced acute liver injury in mice by activating the Nrf2 signaling pathway, reducing serum ALT, AST, total cholesterol, and triglycerides, improving hepatic inflammatory markers, and increasing superoxide dismutase activity and glutathione content.
• Anti-obesity — Polysaccharides from L. decastes reduced obesity in animal models by altering gut microbiota composition and increasing energy expenditure.

Emerging/Preclinical Indications

• Colitis and gut barrier integrity — L. decastes-derived polysaccharides (200-400 mg/kg) alleviated DSS-induced colitis in mice by suppressing inflammation, enhancing intestinal barrier integrity (upregulating occludin and ZO-1 tight junction proteins), reducing myeloperoxidase activity, and restoring gut microbiota homeostasis with increased beneficial bacteria and reduced pathogenic species.
• Antioxidant activity — Polysaccharide LDSP60-A showed high antioxidant activity with DPPH radical scavenging up to 78.6% and ABTS+ scavenging up to 97.33%, suggesting potential in oxidative stress-related conditions.
• MAPK-mediated immune regulation — A structurally characterized polysaccharide from L. decastes demonstrated immune regulation ability through the MAPK signaling pathway in mice.
• Thrombolytic activity — Preliminary evidence of fibrinolytic enzyme activity from L. decastes, though data remains limited.

Mechanism of Action

Primary Mechanisms

1. Beta-glucan-mediated antitumor immunity Three distinct beta-glucan fractions from L. decastes activate the innate immune system through different structural motifs. The beta-1,3-D-glucan fraction (IV-1, molecular weight 305 kDa) and the beta-1,6-D-glucan fraction (IV-3, 14 kDa) stimulate host-mediated antitumor responses, as evidenced by increased peritoneal macrophage populations and upregulated complement C3-positive fluorescent cells. This indicates activation of both macrophage-mediated phagocytosis and complement-dependent cytotoxicity. The mixed-linkage beta-1,3/1,6-D-glucan (IV-2, 130 kDa) likely engages pattern recognition receptors including Dectin-1 on macrophages and dendritic cells, triggering NF-kB and MAPK downstream signaling cascades.

2. Cholesterol metabolism modulation L. decastes fruiting body components increase the activity of hepatic cholesterol 7-alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in the classical bile acid synthesis pathway. This enzyme converts cellular cholesterol to 7-alpha-hydroxycholesterol, the first step in bile acid biosynthesis. The resulting increase in bile acid production and fecal bile acid excretion effectively reduces circulating cholesterol levels by diverting hepatic cholesterol toward catabolism rather than lipoprotein secretion.

3. Nrf2 pathway activation for hepatoprotection L. decastes polysaccharide (LDFP) activates the nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant response pathway. LDFP upregulates Nrf2 expression while downregulating its cytoplasmic inhibitor Keap1, allowing Nrf2 translocation to the nucleus where it drives expression of cytoprotective genes including heme oxygenase-1 (HO-1) and copper-zinc superoxide dismutase (CuZn-SOD). This cascade enhances cellular antioxidant defenses and reduces oxidative liver injury.

Secondary Mechanisms

• Gut microbiota modulation: L. decastes polysaccharides serve as fermentable substrates for beneficial colonic bacteria, promoting the growth of short-chain fatty acid (SCFA)-producing species while suppressing pathogenic populations. In colitis models, this restoration of microbial homeostasis correlated with reduced intestinal inflammation and improved barrier integrity.
• MAPK signaling in immune cells: Polysaccharides from L. decastes activate mitogen-activated protein kinase (MAPK) pathways in macrophages, enhancing cytokine production and phagocytic activity as part of innate immune regulation.
• Insulin sensitivity enhancement: The antidiabetic mechanism appears to involve improved peripheral insulin sensitivity rather than increased pancreatic insulin secretion, as evidenced by simultaneous reductions in both blood glucose and serum insulin in diabetic mice.

Key Active Compounds

Clinical Evidence Summary

There are no published human clinical trials for Lyophyllum decastes. All pharmacological evidence comes from in vitro and in vivo animal studies. The following table summarizes key preclinical studies.

Key Preclinical Studies

Evidence Limitations

• No human clinical trials have been conducted for any therapeutic indication.
• All pharmacological data comes from rodent models and in vitro systems.
• Dosing in animal studies has not been translated to human-equivalent doses through formal pharmacokinetic studies.
• Most antitumor studies used the Sarcoma 180 transplanted tumor model, which has limited translational relevance to human cancers.
• The lipid-lowering study used a very high dietary concentration (10% by weight), which may not reflect achievable human intake levels.
• Polysaccharide fractions used in studies vary in isolation methods and purity, making cross-study comparisons difficult.
• Long-term safety studies beyond food consumption history are lacking.

Safety Profile

General Assessment

Lyophyllum decastes has been consumed as a food mushroom in Japan for decades and is commercially cultivated and sold in supermarkets. No adverse effects from dietary consumption have been reported in the scientific literature. The mushroom has a long history of safe use as a culinary ingredient. Safety data for concentrated extracts or supplement-dose polysaccharide fractions are limited to animal studies.

Contraindications

• Known mushroom allergy: Individuals with documented allergies to basidiomycete mushrooms should avoid L. decastes.
• Pregnancy and lactation: No specific safety data exists for supplemental doses. Culinary consumption is likely safe based on traditional use, but concentrated extract supplementation should be avoided until safety data are available.

Drug Interactions

• Potential (theoretical): Based on demonstrated lipid-lowering activity, concurrent use of concentrated L. decastes extracts with statins or other lipid-lowering medications could theoretically produce additive effects. No clinical drug interaction studies have been conducted.
• Potential (theoretical): Given antidiabetic activity in animal models, concurrent use with insulin or oral hypoglycemic agents could theoretically increase hypoglycemia risk. No clinical data exist.
• Immune-modulating properties: As with other beta-glucan-containing mushrooms, theoretical concerns exist regarding concurrent use with immunosuppressant medications.

Side Effects

• From food consumption: No documented adverse effects from culinary use at normal dietary amounts.
• From extracts: No adverse effects reported in animal studies at the doses tested.
• General mushroom considerations: Gastrointestinal discomfort (bloating, gas) may occur with high-dose polysaccharide supplementation due to prebiotic fermentation effects in the colon.

Clinical Dosage

As Culinary Food

• Fresh fruiting body: No specific therapeutic dose established; consumed ad libitum as part of Japanese cuisine (typically 50-150 g per serving in dishes)
• Dried fruiting body: Commonly used in soups, hot pots, and stir-fry preparations

Extrapolated from Animal Studies (No Human Validation)

• Hot water extract: Animal studies used 10% dietary supplementation (approximately equivalent to 500 mg/kg body weight in rats). Human-equivalent doses have not been formally calculated or validated.
• Water extract (antidiabetic): 500 mg/kg in mice; allometric scaling to human doses has not been performed
• Polysaccharide fractions (anti-colitis): 200-400 mg/kg in mice; no human dose established

Preparation Notes

• The fruiting body is edible when cooked and has a pleasant, firm texture described as resembling fried chicken, which gives the mushroom its common English name.
• Hot water extraction (decoction) is the primary method used in pharmacological research to isolate bioactive polysaccharides.
• Ultrasound-assisted extraction has been shown to improve polysaccharide yield and bioactivity in research settings.

Sources

• Ukawa Y, Ito H, Hisamatsu M. Antitumor effects of (1—>3)-beta-D-glucan and (1—>6)-beta-D-glucan purified from newly cultivated mushroom, Hatakeshimeji (Lyophyllum decastes Sing.). Int J Med Mushrooms. 2000;2(2):161-170
• Ukawa Y, Izumi Y, Ohbuchi T, et al. Effect of Hatakeshimeji (Lyophyllum decastes Sing.) Mushroom on serum lipid levels in rats. J Nutr Sci Vitaminol (Tokyo). 2002;48(1):73-76
• Miura T, Kubo M, Itoh Y, et al. Antidiabetic activity of Lyophyllum decastes in genetically type 2 diabetic mice. Biol Pharm Bull. 2002;25(9):1234-1237
• Jiang X, et al. Lyophyllum decastes fruiting body polysaccharide alleviates acute liver injury by activating the Nrf2 signaling pathway. Food Funct. 2022;13(4):2323-2335
• Guo Y, et al. Structural characterization of an antioxidant polysaccharide isolated from the fruiting bodies of Lyophyllum decastes. J Food Compos Anal. 2023;124:105604
• Zhang W, et al. Effects of polysaccharides from Lyophyllum decastes (Fr.) Singer on gut microbiota via in vitro-simulated digestion and fermentation. Front Microbiol. 2023;14:1083917
• Wang Z, et al. Polysaccharides from Lyophyllum decastes reduce obesity by altering gut microbiota and increasing energy expenditure. Carbohydr Polym. 2022;295:119862
• Li Y, et al. Structural characterization of a polysaccharide from Lyophyllum decastes with MAPK-mediated immune regulation ability in mice. Int J Biol Macromol. 2023;236:123978
• Zeng W, et al. Lyophyllum decastes-derived polysaccharides alleviate DSS-induced colitis in mice by suppressing inflammation, enhancing intestinal barrier integrity, and restoring gut microbiota homeostasis. Front Pharmacol. 2025;16:1644325
• Hagiwara SY, et al. Ultrasound-Assisted Extraction of Polysaccharides from Lyophyllum decastes: Structural Analysis and Bioactivity Assessment. Molecules. 2025;30(4):894
• Li Y, et al. Structural characterization and immune activity evaluation of a polysaccharide from Lyophyllum decastes. Int J Biol Macromol. 2024;278:134833

Connections

• Maitake — Another Japanese culinary-medicinal mushroom with well-characterized beta-glucan immunomodulatory properties (D-fraction, MD-fraction). Maitake has more advanced clinical evidence for immune modulation and represents the gold standard for medicinal mushroom beta-glucans.
• Shiitake — Premier Japanese culinary-medicinal mushroom. Lentinan (beta-1,3/1,6-D-glucan) from shiitake is an approved pharmaceutical in Japan for cancer adjunctive therapy, providing a model for potential L. decastes polysaccharide development.
• Hypsizygus tessellatus — Buna-shimeji, another cultivated Japanese mushroom in a related ecological niche. Both are valued in Japanese cuisine and share immunomodulatory polysaccharide profiles.
• Turkey Tail — Contains PSK (Krestin) and PSP polysaccharide-protein complexes with the most advanced clinical evidence for beta-glucan-mediated cancer adjunctive therapy. Potential synergy with L. decastes beta-glucans through activation of complementary immune pathways.
• Flammulina velutipes — Enokitake, another popular Japanese culinary mushroom with immunomodulatory and antitumor polysaccharides, providing a useful comparator species.